The litigation targets statements made by Embecta between November 25, 2025, and May 4, 2026. During this period, management repeatedly described the company’s core pen needle portfolio as resilient and resolute. Plaintiffs contend these assurances masked significant market volume softness and the loss of a major customer, realities that allegedly remained undisclosed until the company’s second-quarter fiscal 2026 report.
In section Releases
Embecta Faces Shareholder Lawsuit Over Insulin Pen Needle Sales
A class action lawsuit filed in New Jersey alleges that Embecta Corp. misled investors by touting the stability of its insulin pen needle business while the company faced hidden competitive losses. Hagens Berman is now investigating these claims, which center on a dramatic financial reversal that wiped out over half the firm's stock value.
On May 5, 2026, the company’s narrative collapsed. Embecta revealed a sharp revenue decline, slashed its full-year adjusted EPS guidance by 43%, and cut its quarterly dividend from $0.15 to $0.01 per share. The market reaction was swift, sending the stock price tumbling 57.8% in a single day. Reed Kathrein, a partner at Hagens Berman, noted that the firm is examining whether these prior executive assurances constitute actionable securities violations. Investors who held stock during the class period have until August 17, 2026, to file as lead plaintiffs.
Comments (0)
No comments yet. Be the first!